Hackensack, NJ – January 19, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it has retained Hayden IR, a premier national investor relations consulting firm, to develop and execute strategic investor relations campaigns designed to increase awareness and enhance shareholder value.

Hackensack, NJ – November 29, 2016 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October  31, 2016.

HACKENSACK, NJ - November 17, 2016 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today the signing of a $2 million contract with a large pharmaceutical customer. This is the largest pre-clinical pharmacology contract in the company’s history and is almost double the size of the largest previous contract. The contract includes studies utilizing Champions patient derived xenograft (PDX) models and a significant component of work on immune oncology drugs. Champions continues to invest in its capabilities for customers interested in testing immune oncology drugs and this contract represents an important step forward in commercializing these capabilities.

Hackensack, NJ – September 9, 2016 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2016.

Hackensack, NJ – July 28, 2016 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2016.